Janux Therapeutics, Inc. beat EPS estimates 100% of the time across 1 reported quarters (1 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.31 | — | — | Miss |
| Q1 FY2026 | $-0.52 | — | — | Miss |
| Q12026 FY2026 | $-0.50 | $-0.39 | +22.0% | Beat |
| 2026-02-26 | $-0.65 | — | — | Miss |
Back to JANX overview · JANX holders · JANX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.